It sure was.
If you refer to page 15 of the company presentation, you'll note that Phylogica's peptide 1746 is highlighted for their vaccine program and that the company mentions that their FPP-peptide vaccine has the potential to synergize with existing immunotherapies. Note, that was using their first generation CPPs. Second generation CPPs is what my attention is on next. Have a read of this article re vaccines and immunotherapy to get a better understanding of how Phylogica could potentially play a role in this exciting field.
Hope this helps.
Tony
Ann: First Competitive Read Out - Peptide Vaccine, page-17
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.24 |
Change
0.040(3.33%) |
Mkt cap ! $708.6M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.24 | $1.19 | $1.500M | 1.241M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 204320 | $1.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 4333 | 2 |
View Market Depth
| Last trade - 16.11pm 24/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |